Search

Glenn D Prestwich

from Port Townsend, WA
Age ~76
Get Report
Also known as:
Glenn Dr Prestwich, Glenn Downes Prestwich, Glenn D Bentley, Glenn D Pretwich, Gail Prestwich
Connected to:
Hope R Prestwich, 84Neil B Prestwich, 72Rachel Prestwich, 48Sheri Prestwich, 48Chrissy Prestwood, 43Jan M Prestwood, 71Jennie S Prestwood, 62Jessica Prestwood, 73Kelly L Prestwood, 53Larry N Prestwood, 53

Glenn Prestwich Phones & Addresses

  • Port Townsend, WA
  • Poulsbo, WA
  • 1500 Sunnydale Dr, Salt Lake City, UT 84108
  • 143 E 1St Ave #305, Salt Lake City, UT 84103
  • Spokane, WA
  • Richmond, CA
  • Eastsound, WA
  • Olga, WA
  • Ammon, ID

Business Records

Name / Title
Company / Classification
Phones & Addresses
Glenn Prestwich
Chief Security Officer
ECHELON BIOSCIENCES INC
Lipid Related Research and Drug Discovery · Research & Development in Biotechnology
675 Arapeen Dr STE 302, Salt Lake City, UT 84108
(801) 588-0455, (801) 588-0497

Publications

Us Patents

Assaying Apparatus, Kit, And Method For Lipids And Associated Enzymes

View page
US Patent:
7067269, Jun 27, 2006
Filed:
Nov 26, 2001
Appl. No.:
09/991933
Inventors:
Beth E. Drees - Park City UT, US
Glenn D. Prestwich - Salt Lake City UT, US
Paul O. Neilsen - Draper UT, US
Leena Chakravarty - Sandy UT, US
Michael J. Mostert - Salt Lake City UT, US
Assignee:
Echelon Biosciences, Inc. - Salt Lake City UT
International Classification:
G01N 33/53
US Classification:
435 793, 435 71, 436164, 436172
Abstract:
A lipid assay method, kit, and apparatus involving exposure of a protein, having a lipid recognition motif that interacts with a target lipid and a competing lipid, to a solution containing the competing lipid, and determining whether the target lipid is present in the solution. The target lipid has a stronger affinity to the lipid recognition motif than does the competing lipid. The lipid recognition motif is preferably a pleckstrin homology (PH) domain, with the target lipid being a phosphoinositide. The assay determines activity of a lipid kinase, the target lipid being a phosphorylation product of a reaction between the lipid kinase and a substrate lipid. The assay can be a cancer screening method for detection of cancer cells, where detection of certain levels of a PI(3,4,5)Ptarget lipid is an indicator of a cancer cell.

Compounds And Methods Of Use Thereof For Assaying Lysophospholipase D Activity

View page
US Patent:
7459285, Dec 2, 2008
Filed:
Dec 9, 2003
Appl. No.:
10/732166
Inventors:
Colin Ferguson - Salt Lake City UT, US
Glenn Prestwich - Salt Lake City UT, US
Assignee:
Echelon Biosciences Incorporated - Salt Lake City UT
International Classification:
C12Q 1/44
C12Q 1/34
US Classification:
435 19, 435 18
Abstract:
Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening(HTS) for identification of potential inhibitors of lysoPLD activity.

Crosslinked Compounds And Methods Of Making And Using Thereof

View page
US Patent:
7928069, Apr 19, 2011
Filed:
Oct 2, 2008
Appl. No.:
12/244135
Inventors:
Glenn D. Prestwich - Salt Lake City UT, US
Xiao Zheng Shu - Salt Lake City UT, US
Yi Luo - Harriman NY, US
Kelly R. Kirker - Salt Lake City UT, US
Yanchun Liu - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 38/16
US Classification:
514 172, 514 212, 530350, 530353, 530354, 530356, 530402, 530345
Abstract:
Described herein are crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) die oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one thiol compound with at least one thiol-reactive compound.

Modified Macromolescules And Associated Methods Of Synthesis And Use

View page
US Patent:
7981871, Jul 19, 2011
Filed:
Dec 6, 2004
Appl. No.:
10/581571
Inventors:
Glenn D. Prestwich - Salt Lake City UT, US
Xiao Zheng Shu - Salt Lake City UT, US
Yanchun Liu - Franklin TN, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A01N 43/04
A01N 25/00
A61K 31/715
A61K 31/727
A61K 47/00
A61K 9/14
A61K 9/50
C07H 5/04
C07H 5/06
C08B 37/00
C08B 37/10
US Classification:
514 54, 514 56, 514777, 536 187, 536 21, 424488, 424499
Abstract:
Described herein are compounds such as macromolecules that have been modified in order to facilitate crosslinking by introduction of at least one hydrazide-reactive group and/or aminooxy-reactive group, and methods of making and using thereof for scar-free wound healing, for delivering bioactive agents or living cells, for preventing adhesion after a surgical procedure or for bone and cartilage repair. The macromolecule can be an oligonucleotide, a necleic acid, a polypeptide, a lipid, a glycoprotein, a glycolipid, a polysaccharide, a protein or a synthetic polymer, preferably a glycosaminoglycan like hyaluronan.

Compounds And Methods Of Use Thereof For Assaying Lysophospholipase D Activity

View page
US Patent:
7989663, Aug 2, 2011
Filed:
Oct 28, 2008
Appl. No.:
12/290293
Inventors:
Colin Ferguson - Salt Lake City UT, US
Glenn Prestwich - Eastsound WA, US
Assignee:
Echelon Biosciences Incorporated - Salt Lake City UT
International Classification:
C07F 9/02
US Classification:
568 8, 435 18, 435 19, 568 16, 554 78
Abstract:
Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening (HTS) for identification of potential inhibitors of lysoPLD activity.

Anti-Adhesion Composites And Methods Of Use Thereof

View page
US Patent:
8324184, Dec 4, 2012
Filed:
May 13, 2004
Appl. No.:
10/556693
Inventors:
Glenn D. Prestwich - Salt Lake City UT, US
Kelly R. Kirker - Bozeman MT, US
Steven D. Gray - Salt Lake City UT, US
Janice Gray, legal representative - Salt Lake City UT, US
Xiao Zheng Shu - Dublin CA, US
Hao Li - San Diego CA, US
Yanchun Liu - Nashville TN, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 31/728
A61K 31/717
A61K 31/405
A61K 9/70
A61K 9/00
US Classification:
514 54, 514 57, 514411, 424422, 424443, 424488
Abstract:
Described herein are composites that inhibit or reduce adhesion between two or more tissues. Also described herein are methods of using the composites.

Methods For Treating Interstitial Cystitis

View page
US Patent:
8343942, Jan 1, 2013
Filed:
Mar 23, 2011
Appl. No.:
13/069860
Inventors:
Siam Oottamasathien - Salt Lake City UT, US
Wanjian Jia - Salt Lake City UT, US
Glenn D. Prestwich - Eastsound WA, US
Lindsi McCoard - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 31/728
A61K 9/00
C08B 37/08
A61P 27/02
A61P 27/04
US Classification:
514 54, 514 62, 536 551, 424400, 424427
Abstract:
Described herein are methods for treating interstitial cystitis in a subject comprising administering to the subject an effective amount of a compound which is.

Compounds And Methods Of Use Thereof For Assaying Lysophospholipase D Activity

View page
US Patent:
8512971, Aug 20, 2013
Filed:
May 12, 2010
Appl. No.:
12/800339
Inventors:
Colin Ferguson - Salt Lake City UT, US
Glenn Prestwich - Salt Lake City UT, US
Damian Madan - Salt Lake City UT, US
Assignee:
Echelon Biosciences, Inc. - Salt Lake City UT
International Classification:
C12Q 1/44
C12Q 1/34
US Classification:
435 19, 435 18, 568 16, 554 78
Abstract:
Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening (HTS) for identification of potential inhibitors of lysoPLD activity.
Control profile
Glenn D Prestwich from Port Townsend, WA, age ~76 Get Report